AzTrials
AzTrials

Cognitive AgingAge-WellNCT02977819

Study in Cognitively Intact Seniors Aiming to Assess the Effects of Meditation Training

A study testing Meditation practice and Learning English as a foreign language in people with Cognitive Aging, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

As the number of older people in Europe grows, increasing healthy life years is a priority. As people live longer, ensuring good mental as well as physical health into later years is becoming ever more important. Cognitive decline, dementia (e.g. Read more about this study

Who is it for?
Ages 65 years and olderHealthy volunteers can take part
Conditions the study is for
Cognitive Aging
What is being tested?
Meditation practice and Learning English as a foreign language
Could I receive a placebo?
No, everyone receives an active treatment
How many people
137 participants
Where
1 siteFrance
Study dates
24 Nov 2016to 9 Dec 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • Healthy volunteers accepted
  • Older adult
  1. Inclusion Criteria : For all participants
  • Age ≥ 65 years ;
  • To be autonomous
  • Live in their home;
  • Educational level ≥ 7 years (from the Preparatory Course (First grade) included);
  • To be registered to the social security system ;
  • To be motivated to effectively participate in the project and to sign the consent form in agreement with the local ethic committee ;
  • Neuropsychological performances within the normal range (according to age, sex, and educational level), as assessed by the diagnostic battery. For participants without previous meditation practice
  • French mother tongue;
  • Available for the trial duration (24 months);
  • Retired since 1 year or more;
  • No preference regarding the intervention group ;
  • Not having regularly or intensively practiced meditation or comparable practices (yoga, Qi Gong, Alexander technique) as follows :
  • more than one day per week for more than six months consecutively over the last 10 years,
  • intensively (internship or retreat > five consecutive days) over the past 10 years,
  • more than 25 days of retreats (cumulatively) prior to the last 10 years ;
  • Not speaking English fluently. For expert meditators :
  • Formal meditation practice > 10 000 hours in the whole life, including at least 6 cumulated months of retreat;
  • Daily meditation practice (at least 6 days/week, 45 minutes/day);
  • Mindfulness meditation practice (i.e. mindfulness, samatha/vipassana, zazen (zen), shikantaza (zen), focused attention, mahamudra/Dzogchen, and compassion/loving jindness (tonglen, metta/karuna, bodhichitta)
  1. Exclusion criteria :
  • Contraindication to MRI or PET Amyvid® ;
  • For security reasons realted with the use of Amyvid®, a blood sampling allowing to measure hepatic and renal functions will be performed at the V1 visit before the PET-Amyvid® scan. In case anomalies are detected of grade 3 or higher severity, the PET-Amyvid® scan will not be performed.
  • Hypersensitivity to Amyvid®
  • History or presence of a major neurological or psychiatric disorder (including an addiction to alcohol or drugs);
  • History of cerebral disease (vascular, degenerative, physical malformation, tumor, or head trauma with loss of consciousness for more than an hour);
  • Presence of a chronic disease or acute unstable illness (respiratory, cardiovascular, digestive, renal, metabolic, hematologic, endocrine or infectious);
  • Current or recent medication that may interfere with cognitive action or radiological measures (psychotropic drugs, antihistamines, anti-Parkinsonian drugs, benzodiazepines, non-steroidal anti-inflammatory agents, antiepileptics, central analgesic and muscle relaxants);
  • Under legal guardianship or incapacitation;
  • Inclusion in another biomedical research protocol at baseline, if including use of a radiolabel for radiological measures;
  • Physical of behavioural inhabilities to perform the follow-up visits as planned in the study protocol.

Trial locations and contacts

1 site in 1 country.

France1 site

  • GIP Cyceron

    Caen, Calvados, 14000

Other trials in France

About this study

Official title: Interventional Study in Cognitively Intact Seniors Aiming to Assess the Effects of Meditation Training and Foreign Language Learning on Behavioral, Biological and Neuroimaging Measures

As the number of older people in Europe grows, increasing healthy life years is a priority. As people live longer, ensuring good mental as well as physical health into later years is becoming ever more important. Cognitive decline, dementia (e.g. Alzheimer's Disease, AD), sleep disturbances and depression, all related to psychological distress and anxiety, are significant drivers of reduced quality of life in older adults. This project builds on evidence that meditation practice have the potential to downregulate these adverse factors and positively impact mental and neurological conditions including AD.

Read the detailed description

Understanding of the neurocognitive mechanisms of meditation is still limited. Meditation can be conceptualized as "a set of complex emotional and attentional regulation strategies developed for a variety of purposes including the development of emotional well-being and balance". Affective (emotional) and cognitive (attentional) control are therefore the most likely mechanisms by which meditation could impact aging and AD. Specifically, meditation could enhance the controlling role of mid-brain structures and the executive network over structures involved in memory, emotions, and regulation of the immune system. This would lead to better emotional and cognitive control which in turn would be associated with improved mental and physical health.

Conditions
Cognitive Aging
Being tested
Meditation practice, Learning English as a foreign language

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Meditation practiceOther

    18 months

  • Learning English as a foreign languageOther

    18 months

Study groups in NCT02977819
Study groupRoleWhat they receive
Meditation programExperimentalMeditation courses and at-home practice
Receives: Other: Meditation practice
English learning coursesActive comparatorEnglish learning courses and at-home practice
Receives: Other: Learning English as a foreign language
No interventionNo interventionFollow-up without Meditation courses or English Learning courses

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Estimate the effect of an 18-month meditation intervention in non-meditating senior participants on the volume of the anterior cingulate cortex compared to a passive control intervention

    change in anterior cingulate cortex volume (T1-weighted MRI)

    Measured: Visit 1 inclusion - Visit 3 Month 18

  2. Estimate the effect of an 18-month meditation intervention in non-meditating senior participants on the perfusion of the anterior cingulate cortex compared to a passive control intervention

    change in anterior cingulate cortex perfusion (early PET-Amyvid® scan)

    Measured: Visit 1 inclusion - Visit 3 Month 18

  3. Estimate the effect of an 18-month meditation intervention in non-meditating seniors on the volume of the insula compared to an 18 months intervention of learning a foreign language

    change in insula volume (T1-weighted MRI)

    Measured: Visit 1 inclusion - Visit 3 Month 18

  4. Estimate the effect of an 18-month meditation intervention in non-meditating seniors on the perfusion of the insula compared to an 18 months intervention of learning a foreign language

    change in insula perfusion (early PET-Amyvid® scan)

    Measured: Visit 1 inclusion - Visit 3 Month 18

Secondary outcomes (35)

  1. Comparison between meditation intervention and language learning intervention on the global metacognitive composite score

    consisting in the mean of the attentional, constructive and deconstructive subscores (main behavioural outcome) Each composite score is computed by averaging its respective standardised scale scores (range (-3) - (4) , Higher score of the meditation composite score mean better outcome)

    Measured: up to 35 months post intervention

  2. Composite score per cognitive area assessed by the neuropsychological tests and the questionnaires

    composite scores will be computed as z-scores calculated from all the cognitive scores obtained for the corresponding cognitive function that will have a normal distribution and will not have a floor or ceiling effect. Additional exploratory analyses will be conducted on all individual behavioural measures obtained.

    Measured: up to 35 months post intervention

  3. Medical neuroimaging using MRI: grey and white matter volume in all brain voxels

    grey and white matter volume in all brain voxels

    Measured: up to 35 months post intervention

  4. Medical neuroimaging using MRI: hippocampal and hippocampal subfield volumes

    hippocampal and hippocampal subfield volumes

    Measured: up to 35 months post intervention

  5. Medical neuroimaging using MRI: brain perfusion in all brain voxels

    brain perfusion in all brain voxels

    Measured: up to 35 months post intervention

  6. Medical neuroimaging using MRI: fractional anisotropy and mean diffusivity in all brain voxels

    fractional anisotropy and mean diffusivity in all brain voxels

    Measured: up to 35 months post intervention

  7. Medical neuroimaging using MRI: number, size, type and location of white matter lesions

    number, size, type and location of white matter lesions

    Measured: up to 35 months post intervention

  8. Medical neuroimaging using MRI: magnetic susceptibility index in all brain voxels

    magnetic susceptibility index in all brain voxels

    Measured: up to 35 months post intervention

  9. Medical neuroimaging using MRI: brain functional connectivity measures in all brain voxels at rest in a non-meditative state

    brain functional connectivity measures in all brain voxels at rest in a non-meditative state

    Measured: up to 35 months post intervention

  10. Beta-amyloid charge (of the radiopharmarceutical Amyvid®) measured in each voxel of the brain and gross mean in gray matter

    measured in each voxel of the brain and gross mean in gray matter

    Measured: up to 35 months post intervention

  11. Glucose Cerebral Consumption at rest (relative to mean consumption measured in the cerebellum)

    Glucose Cerebral Consumption at rest (relative to mean consumption measured in the cerebellum) by TEP

    Measured: up to 35 months post intervention

  12. Medical neuroimaging using fMRI: Brain activity specifically associated with emotional processes (comparing emotional to neutral items) during the Rest-SoVT task.

    Brain activity specifically associated with emotional processes (comparing emotional to neutral items) during the Rest-SoVT task.

    Measured: up to 35 months post intervention

  13. Medical neuroimaging using fMRI: Brain activity specifically associated with attentional processes (altertness, inhibition, sustained attention) during the AX-CPT task.

    Brain activity specifically associated with attentional processes (altertness, inhibition, sustained attention) during the AX-CPT task.

    Measured: up to 35 months post intervention

  14. Medical neuroimaging using PET-scan and Amyvid® radiotracer

    Brain amyloid load (of the PET-Amyvid® radiotracer) measured in global grey matter mask

    Measured: up to 35 months post intervention

  15. Subjectives sleep measures with sleep quality index z-score mean of the scores at questionnaires

    Epworth scale, Leeds Sleep evaluation questionnaire, Pittsburg Sleep Quality Scale, St Mary's hospital questionnaire, Berlin Questionnaire, and Insomnia severity index.

    Measured: up to 35 months post intervention

  16. Mean duration of sleep

    Data collected by actimetrics record

    Measured: up to 35 months post intervention

  17. fragmentation indices during activity and resting states

    Data collected by actimetrics record

    Measured: up to 35 months post intervention

  18. regularity of the rest-activity cycle

    Data collected by actimetrics record

    Measured: up to 35 months post intervention

  19. Mean z-score of total sleep time

    Data collected during polysomnographic sleep record with Somno-Art device

    Measured: up to 35 months post intervention

  20. Mean z-score of sleep onset latency

    Data collected during polysomnographic sleep record with Somno-Art device

    Measured: up to 35 months post intervention

  21. Mean z-score of sleep efficiency

    Data collected during polysomnographic sleep record with Somno-Art device

    Measured: up to 35 months post intervention

  22. Biological blood tests

    tau, phosphotau, Ab 40, 42, APOE4, NFL, BDNF, GWAS, cytokines, CRP, cortisol, serotonine, SDHEA, SHBG, E2, testosterone, glycemie, insuline, BNP, tPA, PAI-1, peroxyredoxine

    Measured: up to 35 months post intervention

  23. Telomerase properties by blood tests

    Telomerasic activity, telomerase length

    Measured: visit 1 baseline -Visit 3 18 months

  24. lymphocytic immunophenotyping

    biological blood tests

    Measured: visit 1 baseline -Visit 3 18 months

  25. Difference in partner perceptions of participant mindfulness measured by Five-Facet Mindfulness Questionnaire (FFMQ-15, range 15-75, higher scores indicate greater mindfulness)

    Partners are defined as spouse, sibling, child, neighbour or friend in close contact with the participant.

    Measured: up to 35 months post intervention

  26. Difference in partner perceptions of participant compassion towards others measured by Compassionate Love Scale (Range 21-147, higher scores indicate greater compassion)

    Partners are defined as spouse, sibling, child, neighbour or friend in close contact with the participant

    Measured: up to 35 months post intervention

  27. Difference in partner perceptions of participant depression measured by the Geriatric Depression Scale (range 0-15, higher scores indicate greater depressive symptoms)

    Partners are defined as spouse, sibling, child, neighbour or friend in close contact with the participant

    Measured: up to 35 months post intervention

  28. Scores to evaluate the impact on volunteers' relatives

    scores to hetero questionnaires fulfilled by relatives and qualitative data from interviews with the participants on one hand and with the teachers on the other hand

    Measured: up to 35 months post intervention

  29. Difference in partner perceptions of participant anxiety measured by trait subscale of the state-trait anxiety inventory (trait-STAI, range 20-80, higher scores indicate greater anxiety symptoms)

    Partners are defined as spouse, sibling, child, neighbour or friend in close contact with the participant

    Measured: up to 35 months post intervention

  30. Difference in partner perceptions of participant prosocialness measured by Prosocialness scale (range 16-80, higher scores indicate greater prosocialness)

    Partners are defined as spouse, sibling, child, neighbour or friend in close contact with the participant

    Measured: up to 35 months post intervention

  31. Difference in partner perceptions of participant's cognitive difficulties in everyday life, measured by Mc Nair CDS (range 0-156, higher score indicates greater cognitive difficulties)

    Partners are defined as spouse, sibling, child, neighbour or friend in close contact with the participant

    Measured: up to 35 months post intervention

  32. Neural signature of meditative practices using brain medical imaging (neuronal activity in each cerebral voxel (fMRI) at rest and during the emotional task, in a mindfulness meditative state versus not; in compasional meditative state or not)

    only for meditation experts

    Measured: up to 35 months post intervention

  33. Safety and acceptance

    recording adverse events, measurement of anxiety, depression, satisfaction, and well-being using questionnaires

    Measured: up to 35 months post intervention

  34. evaluation of the practice of the meditation practice and language learning at long-term (29 months post-intervention)

    questionnaire about the practice (meditation or foreign language)

    Measured: up to 35 months post intervention (because V4 = 29 months post intervention with a window of 6 months

  35. Behavioral measures (questionnaires) to evaluate the psychological impact of the confinement

    composite score per function (anxiety, stress, auto-compassion...)

    Measured: up to 35 months post intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Nov 2016 (estimated)
  2. Study start24 Nov 2016
  3. Primary completion31 Dec 2019
  4. Study completion9 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
137 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02977819
Sponsor's protocol ID
C16-38
Other IDs
2016-A01767-44
Acronym
Age-Well
Status last verified
Feb 2025
First submitted
4 Nov 2016
Last updated
10 Feb 2025
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Yes: Data access of AGE-WELL and SCD-WELL studies of the MEDIT-AGEING project for which Institut national de la santé et de la recherche médicale (Inserm) is the sponsor. The Material can be mobilized, under the conditions and modalities defined in the Charter, by any research team belonging to an Academic signatory to the Consortium Agreement concluded for the needs of the Project or by any research team belonging to an Academic outside the Consortium Agreement, French or foreign, for carrying out SRP relating to the scientific theme of mental health and wellbeing in older people. The Material may also be mobilized, by non-academic third parties for the realization of SRP relating to the scientific theme of mental health and wellbeing in older people, under conditions, in particular financial, which will be established by separate agreement between Inserm and by the said third party.

Publications

  • Poisnel G, Arenaza-Urquijo E, Collette F, Klimecki OM, Marchant NL, Wirth M, de La Sayette V, Rauchs G, Salmon E, Vuilleumier P, Frison E, Maillard A, Vivien D, Lutz A, Chetelat G; Medit-Ageing Research Group. The Age-Well randomized controlled trial of the Medit-Ageing European project: Effect of meditation or foreign language training on brain and mental health in older adults. Alzheimers Dement (N Y). 2018 Dec 14;4:714-723. doi: 10.1016/j.trci.2018.10.011. eCollection 2018.

    PubMed 30581977

  • Chetelat G, Lutz A, Klimecki O, Frison E, Asselineau J, Schlosser M, Arenaza-Urquijo EM, Mezenge F, Kuhn E, Moulinet I, Touron E, Dautricourt S, Andre C, Palix C, Ourry V, Felisatti F, Gonneaud J, Landeau B, Rauchs G, Chocat A, Quillard A, Devouge EF, Vuilleumier P, de La Sayette V, Vivien D, Collette F, Poisnel G, Marchant NL; Medit-Ageing Research Group. Effect of an 18-Month Meditation Training on Regional Brain Volume and Perfusion in Older Adults: The Age-Well Randomized Clinical Trial. JAMA Neurol. 2022 Nov 1;79(11):1165-1174. doi: 10.1001/jamaneurol.2022.3185.

    PubMed 36215061

  • Schlosser M, Klimecki OM, Collette F, Gonneaud J, Kliegel M, Marchant NL, Chetelat G, Lutz A; Medit-Ageing Research Group. An 18-month meditation training selectively improves psychological well-being in older adults: A secondary analysis of a randomised controlled trial. PLoS One. 2023 Dec 1;18(12):e0294753. doi: 10.1371/journal.pone.0294753. eCollection 2023.

    PubMed 38039341

  • Montagne B, Boulin M, Hamel A, Champetier P, Rehel S, Mezenge F, Landeau B, Delarue M, Hebert O, Soussi C, Bertran F, Chetelat G, Andre C, Rauchs G; Medit-Ageing Research Group. Night-to-night rapid eye movement sleep variability: A relevant marker of early amyloid-beta deposition. Alzheimers Dement. 2026 Apr;22(4):e71376. doi: 10.1002/alz.71376.

    PubMed 41996149

  • Foyard E, Blanchard T, Landeau B, Chauveau L, Naveau M, Poisnel G, Bui E, Chetelat G, de Flores R; Medit-Ageing Research Group. Altered locus coeruleus links to atrophy and hypometabolism in individuals with high Alzheimer's disease biomarkers. Alzheimers Dement. 2026 Mar;22(3):e71212. doi: 10.1002/alz.71212.

    PubMed 41772375

  • Lehodey A, Montagne B, Rehel S, Kaliman P, Chocat A, Mezenge F, Landeau B, de la Sayette V, Chetelat G, Rauchs G, Poisnel G; Medit-Ageing Research Group. Telomere dynamics are influenced by sleep, sleep variability and circadian rhythms in older adults with or without alzheimer's risk. Alzheimers Res Ther. 2025 Dec 5;18(1):10. doi: 10.1186/s13195-025-01923-3.

    PubMed 41345970

  • Haudry S, Dautricourt S, Gonneaud J, Landeau B, Calhoun VD, de Flores R, Poisnel G, Bougacha S, Kuhn E, Touron E, Chauveau L, Felisatti F, Palix C, Vivien D, de la Sayette V, Lutz A, Chetelat G. Effects of an 18-month meditation training on dynamic functional connectivity states in older adults: Secondary analyses from the Age-Well randomized controlled trial. Imaging Neurosci (Camb). 2025 Jun 10;3:IMAG.a.33. doi: 10.1162/IMAG.a.33. eCollection 2025.

    PubMed 40800757

  • Champetier P, Hamel A, Andre C, Ourry V, Lacroix T, Rehel S, Chauveau L, Haudry S, Bertran F, de la Sayette V, Vivien D, Chetelat G, Lutz A, Rauchs G; Medit-Ageing Research Group. EEG Brain Rhythms During Resting-State Wakefulness and Sleep in Elderly Expert Meditators. J Sleep Res. 2026 Apr;35(2):e70161. doi: 10.1111/jsr.70161. Epub 2025 Jul 29.

    PubMed 40731281

  • Chauveau L, Gonneaud J, Poisnel G, Landeau B, Garnier-Crussard A, Pitel AL, Roquet D, Touron E, Haudry S, Mezenge F, Chocat A, Vivien D, de La Sayette V, Chetelat G, de Flores R; Medit-Ageing Research Group. Cardiovascular risk factors are associated with lower posterior-medial network functional connectivity in older adults. Alzheimers Res Ther. 2025 Jul 15;17(1):159. doi: 10.1186/s13195-025-01808-5.

    PubMed 40665410

  • Requier F, Mohammadi H, Demnitz-King H, Schlosser M, Poisnel G, Salmon E, Chetelat G, Marchant NL, Lutz A, Collette F; Medit-Ageing Research Group. Examining cognitive differences in expert meditators and non-meditators older adults. Sci Rep. 2025 May 15;15(1):16898. doi: 10.1038/s41598-025-00226-9.

    PubMed 40374672

  • Touron E, de Flores R, Coulbault L, Palix C, Chocat A, Kuhn E, Landeau B, Mezenge F, Roquet D, Chauveau L, Haudry S, Vivien D, de La Sayette V, Marchant NL, Chetelat G, Poisnel G; Medit-Ageing Research Group. Depressive symptoms in older adults are associated with changes in stress-related markers, functional connectivity and brain volume. Alzheimers Res Ther. 2025 Jan 6;17(1):9. doi: 10.1186/s13195-024-01643-0.

    PubMed 39762947

  • Lehodey A, Kaliman P, Palix C, de Flores R, Touron E, Turpin AL, Fauvel S, Mezenge F, Landeau B, Chocat A, Vrillon A, Paquet C, Vivien D, de La Sayette V, Chetelat G, Poisnel G; Medit-Ageing Research Group. Association of critically short telomeres with brain and blood markers of ageing and Alzheimer's disease in older adults. Alzheimers Res Ther. 2024 Dec 20;16(1):269. doi: 10.1186/s13195-024-01635-0.

    PubMed 39707531

  • Garnier-Crussard A, Gonneaud J, Felisatti F, Palix C, Ferrand Devouge E, Chocat A, Rauchs G, de la Sayette V, Vivien D, Demnitz-King H, Lutz A, Chetelat G, Poisnel G; Medit-Ageing Research Group. Effect of an 18-month meditation training on cardiovascular risk in older adults: a secondary analysis of the Age-Well randomized controlled trial. BMC Geriatr. 2024 Nov 16;24(1):954. doi: 10.1186/s12877-024-05550-9.

    PubMed 39550530

  • Requier F, Demnitz-King H, Frison E, Delarue M, Gonneaud J, Chetelat G, Klimecki O, Salmon E, Lutz A, Marchant NL, Collette F; Medit-Ageing Research Group. The evolution of subjective cognition after meditation training in older people: a secondary analysis of the three-arm age-well randomized controlled trial. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2025 Mar;32(2):252-269. doi: 10.1080/13825585.2024.2376783. Epub 2024 Jul 17.

    PubMed 39017643

  • Champetier P, Andre C, Rehel S, Ourry V, Landeau B, Mezenge F, Roquet D, Vivien D, de La Sayette V, Chetelat G, Rauchs G; Medit-Ageing Research Group. Multimodal neuroimaging correlates of spectral power in NREM sleep delta sub-bands in cognitively unimpaired older adults. Sleep. 2024 Apr 12;47(4):zsae012. doi: 10.1093/sleep/zsae012.

    PubMed 38227830

Questions about this trial

What is this clinical trial studying?

A study testing Meditation practice and Learning English as a foreign language in people with Cognitive Aging, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Estimate the effect of an 18-month meditation intervention in non-meditating senior participants on the volume of the anterior cingulate cortex compared to a passive control intervention (time frame: Visit 1 inclusion - Visit 3 Month 18). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02977819, which also lists 22 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in